Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'- thiacytidine

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 12, 1997, Pages 2763-2765

  Cherry, Elana ^a   Slater, Mark ^a   Salomon, Horacio ^a,c   Rud, Erling ^b   Wainberg, Mark A ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b LAB CENTRE FOR DISEASE CONTROL   (Canada)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; RNA DIRECTED DNA POLYMERASE;

ANTIBIOTIC RESISTANCE; CONCENTRATION RESPONSE; DRUG SENSITIVITY; MOLECULAR CLONING; NONHUMAN; NOTE; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SIMIAN IMMUNODEFICIENCY VIRUS; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

EID: 0030778139     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.12.2763     Document Type: Note

References (25)

1. Back, N. K. T., M. Nijhuis, W. Keulen, C. A. B. Boucher, B. B. Oude Essink, A. B. P. van Kuilenburg, A. H. van Gennip, and B. Berkhout. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
2. Balzarini, J., M. Weeger, M.-J. Camarasa, E. De Clercq, and K. Uberla. 1995. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) towards the HIV-1-specific non-nucleoside reverse transcriptase inhibitors. Biochem. Biophys. Res. Commun. 211:850-856.
3. Boucher, C. A. B., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High-level resistance to (-) enantiomer 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
4. Boulerice, F., S. Bour, R. Geleziunas, A. Lvovich, and M. A. Wainberg. 1990. High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J. Virol. 64:1745-1755.
5. Boyer, P. L., and S. H. Hughes. 1995. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 39:1624-1628.
6. Gao, Q., Z. Gu, M. A. Parniak, X. Li, and M. A. Wainberg. 1992. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J. Virol. 66:12-19.
7. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
8. Gao, Q., Z. Gu, M. A. Parniak, X. Li, and M. A. Wainberg. 1992. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J. Virol. 66:12-19.
9. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. A. Wainberg. 1992. A novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes resistance to 2′,3′-dideoxyinosine and cross-resistance to 2′,3′-dideoxycytidine. J. Virol. 66:7128-7135.
10. Kestler, H., T. Kodoma, D. Ringler, M. Marthas, N. Pederson, A. Lackner, D. Regier, P. Sehgal, M. Daniel, N. King, and R. C. Desrosiers. 1989. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 248:1109-1112.
11. Keulen, W., N. K. T. Back, A. van Wijk, C. A. B. Boucher, and B. Berkhout. 1997. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 71:3346-3350.
12. Larder, B. A., K. E. Coates, and S. D. Kemp. 1991. Zidovudine (AZT) resistant human immunodeficiency virus selected by passage in cell culture. J. Virol. 65:5232-5236.
13. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246:1155-1158.
14. Larder, B. A., S. D. Kemp, and D. J. M. Purifoy. 1989. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc. Natl. Acad. Sci. USA 86:4803-4808.
15. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
16. Mitsuya, H., R. F. Jarret, M. Matsukura, F. D. M. Veronese, A. L. DeVico, M. G. Sarngadharn, D. G. Johns, M. S. Reitz, and S. Broder. 1987. Long-term inhibition of human T-lymphotropic virus III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2′,3′-dideoxynucleotides in vitro. Proc. Natl. Acad. Sci. USA 84:2033-2037.
17. Regier, D. A., and R. Desrosiers. 1990. The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res. Hum. Retroviruses 6:1221-1231.
18. Rud, E. W., M. Cranage, J. Yon, J. Quirk, L. Ogilvie, N. Cook, S. Webster, M. Dennis, and B. E. Clarke. 1994. Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J. Gen. Virol. 75:529-543.
19. Schinazi, R. F., R. M. Lloyd, Jr., M.-H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
20. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, S. Kwok, J. Sninsky, and C. A. B. Boucher. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
21. Smith, R. A., K. M. Remington, R. M. Lloyd, Jr., R. F. Schinazi, and T. W. North. 1997. A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides. J. Virol. 71:2357-2362.
22. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
23. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistance to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
24. Van Rompay, K. K. A., J. L. Greenier, M. L. Marthas, M. G. Otsyula, R. P. Tarara, C. J. Miller, and N. C. Pedersen. 1997. A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques. Antimicrob. Agents Chemother. 41:278-283.
25. Wakefield, J. K., S. A. Jablonski, and C. D. Morrow. 1992. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J. Virol. 66:6806-6812.